TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Type 2 diabetic subjects with documented evidence of mild diabetic foot ulcer~* Male or female patients attending Diabetic Clinics and/or Podiatry Clinics at the hospitals of the New Territories East Cluster~* Aged between 20 and 75 years old inclusive~* All patients should be on stable dose of medication 4 weeks prior to enrolment~* Written informed consent~* If the patient is a woman of child-bearing potential, she must agree to use adequate method of contraception throughout the study period, unless surgically sterilized.~Exclusion Criteria:~Patients with end-stage renal disease as defined by the need for dialysis or on renal replacement program~* Patients with advanced diabetic eye disease as defined by the history of laser therapy, retinal detachment or vitreous hemorrhage~* Pregnancy, breast feeding, or patient has plans of becoming pregnant during the study period.~* Known allergy to TCM drugs~* Contraindication or intolerance to use of aspirin, statin , ACEI or ARB~* History of major gastrointestinal bleeding in the 5 years prior to consent~* Congestive heart failure of any severity~* Significant cardiovascular disease within 3 months of enrolment including acute coronary syndrome, cardiac revascularization procedure, transient ischemic attack and cerebrovascular accident~* HbA1c ≥ 10%~* Severe liver function impairment (≥ 3 ULN of ALT) and renal impairment (eGFR \< 30 ml/min/1.73 m2)~* Investigational drugs within 30 days of enrolment~* Patient taking any Chinese herbal medicine in the 8 weeks prior to enrolment into the study~* Any other medical conditions that is considered as unsuitable for the study by investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Chinese Herbal Medicine (Type: ACTIVE_COMPARATOR): 2 sachets of Chinese Herbal Medicine to be taken daily
- Placebo arm (Type: PLACEBO_COMPARATOR): 2 sachets to be taken daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-Patients with chronic myeloid leukemia in the chronic phase diagnosed within 6 months of study entry~Exclusion Criteria:~* Treatment with tyrosine kinase inhibitor or other antileukemic agents or treatments (including HSCT) for longer than 2 weeks, with exception of hydroxyurea and/or anagrelide~* Uncontrolled congestive heart failure or hypertension~* Myocardial infarction or unstable angina pectoris within past 12 months~* Known T315I mutations~* QTcF \>450 msec~* Significant arrhythmias~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): 300 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Insufficiently controlled after 3 months of treatment with OADs (oral anti-diabetic drugs)~Exclusion Criteria:~* Previously treated with liraglutide~* Hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections)~* Pregnant, breast feeding or have the intention of becoming pregnant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos) Phase II

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Proportion Tested: Age 3 or older~* Proportion Tested: Received testing at study testing site~* Individual Survey: 15 or older~Exclusion Criteria:~• Individual Survey: Unable to understand Spanish or English or another language translated by a qualified translator at a 5th grade level

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Partner-optimized venue placement strategy (Type: EXPERIMENTAL): The Phase II intervention involves outreach from community partners to attend testing at existing events organized by community partners, such as the Mexican Consulate. At the event, it includes the on-site Promotores de Salud psychoeducation related to SARS-CoV-2 health related behaviors.
- Active Comparator, Residential density-located venue placement strategy (Type: EXPERIMENTAL): This is the Phase I intervention (Clinical Trial ID: NCT04793464). It includes the Phase I Promotores de Salud intervention, which consists of outreach to promote testing and vaccination at re-occurring testing events that have been selected for sites that have a high residential density of Latinx persons. At the testing events, it includes the on-site Promotores de Salud psychoeducation related to SARS-CoV-2 health related behaviors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Healthy or multiple sclerosis~* Aged 18 to 60~* Body mass index is between 18 kg/m2 and 30 kg/m2~* Screening 25-hydroxyvitamin D level ≤ 75 nmol/L (30 ng/mL)~* White race~* Non-Hispanic ethnicity~* Willing to use birth control during study~* Willing to not use tanning bed during study~If subject has multiple sclerosis:~* Relapsing-remitting MS, as defined by McDonald 2005 criteria~* Screening Expanded Disability Status Scale score ≤ 3.0~* Using no medication for MS, or taking Copaxone, (glatiramer acetate), interferons, or natalizumab~Exclusion Criteria:~* Pregnant or nursing~* Taking multivitamin \& unwilling to remain off it during study~* Taking cod liver oil \& unwilling to remain off it during study~* On a fat-restricted diet~* History of renal disease or nephrolithiasis (kidney stones)~* History of liver disease~* Taking thiazide diuretics~* History of hyperthyroidism~* History of infection with Mycobacterium species~* History of sarcoidosis~* History of cancer~* History of cardiac disease~* History of HIV~* History of gastrointestinal disorder~* Taking medications that interfere with gastrointestinal absorption~* Cigarette smoker in past month~* Use of illicit drugs in past month~* Use of steroids in past month~* History of hypercalcemia, and screening serum calcium ≤ 10 mg/dL (UCSF) or ≤ 10.7 mg/dL (Johns Hopkins)~* History of hypercalciuria~* Evidence of anemia (Hgb \<11.0 g/dL)~* History of other serious medical conditions~* Taking medications that involve the P450 system or may interact with vitamin D (digoxin, diltiazem, verapamil, cimetidine, heparin, or low-molecular weight heparin)~* Other concerns about safety from the perspective of the treating physician~If subject has MS:~-History of major heat sensitivity (leading to sun-avoidant behaviors)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Vitamin D3 (Type: EXPERIMENTAL): Both those with MS and healthy controls will be given vitamin D3 5000 IU/day by mouth for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* Have confirmed laboratory diagnosis of HIV infection~* Presenting with a clinical history of active PML evolving (or continuing to deteriorate) for less than 90 days~* Diagnosis of PML documented for less than 30 days at the inclusion by cerebral imaging (MRI) AND the absence of another demonstrated etiology AND the detection of JCV DNA in the CSF by qualitative PCR.~* Signed written inform consent~Exclusion Criteria:~* Concomitant opportunistic infection of the central nervous system~* Pregnancy, breast-feeding~* Co-infection by the HIV2~* History of immunotherapy including interleukin-2 and alpha-interferon~* History of treatment by FUZEON® or by cidofovir~* Contra-indication to receive FUZEON

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~SLE patients~* Female patients aged ≤ 35 years~* Fulfilling the American College of Rheumatology (ACR) criteria for the classification of SLE~* Having received a stable dose of prednisolone and/or other immunosuppressive agents within 3 months of study entry~* Able to give written informed consent~Controls~* Women aged ≤ 35 years, matched those of SLE patients recruited~* No known chronic medical diseases~* Not receiving any long-term medications including herbs~Exclusion Criteria:~* History of allergy to HPV vaccines

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Vaccine arm (Type: ACTIVE_COMPARATOR): subjects receiving vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of the FreeStyle Navigator Continuous Glucose Monitoring System to Enhance Education and Glycaemic Control

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject with Type 1 or Type 2 diabetes requiring Multiple Daily Injections (MDI) (for \>1yr)~* Age 18-65 years~* HbA1c above 8.0% for previous 2 HbA1c tests; the last HbA1c result being obtained within 3 months prior to enrolment~* Completed a structured education programme meeting NICE criteria between 6 to 24 months prior to enrolment.~* Testing Blood Glucose ≥ 4 times a day for previous 12 months~Exclusion Criteria:~* Subject is currently on an insulin pump.~* Subject has known allergy to medical grade adhesives~* Subject has concomitant disease that influences metabolic control~* Subject is participating in another study of a glucose monitoring device / drug that could affect glucose measurements / management~* Subject is currently using another continuous glucose monitoring device or has previously used real-time continuous glucose monitoring.~* Subject is receiving peritoneal dialysis solutions containing icodextrin~* Subject is pregnant / planning to become pregnant during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Pain Management After Minimally Invasive Aortic Valve Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients after minimally invasive aortic valve surgery~* Patients agreement with the study~Exclusion Criteria:~* Age under 18 years~* Allergy to local anesthetic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ropivacaine continous infusion (Type: ACTIVE_COMPARATOR): Piritramid
- Saline continous (Type: SHAM_COMPARATOR): Piritramid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIAsp 30 users (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are diagnosed with neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.~Exclusion Criteria:~* Severe Pain associated with conditions other than Diabetic Peripheral Neuropathy, Post-Herpetic Neuralgia, Human Immunodeficiency virus related peripheral neuropathy, and chemotherapy induced peripheral neuropathy that may confound assessment or self evaluation of the neuropathic pain.~* Skin Condition in the affected dermatome that (in the judgment of the investigator) could alter sensation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of allogeneic stem cell transplantation with myeloablative or non-myeloablative conditioning regimens~* Patients must be at least 180 days from the allogeneic stem cell transplantation procedure~* Steroid refractory cGVHD, defined as having persistent symptoms and signs of GVHD despite the use of prednisone for at least 4 weeks in the preceding 12 months without complete resolution of signs and symptoms.~* Stable dose of corticosteroids for 4 weeks prior to enrollment~* No addition or subtraction of other immunosuppressive medications for 4 weeks prior to enrollment.~* Adequate bone marrow, renal and hepatic function as outlined in the protocol~* 18 years of age or older~* ECOG Performance Status of 0-2~Exclusion Criteria:~* Ongoing prednisone requirement \> 1mg/kg/day (or equivalent)~* Exposure to any new immunosuppressive medication in the 4 weeks prior to enrollment~* Concurrent ECP therapy within 4 weeks prior to enrollment~* Post-transplant exposure to any novel immunosuppressive medication within 100 days prior to enrollment~* Donor lymphocyte infusion within 100 days prior to IL-2 therapy~* Active malignant disease relapse~* Active, uncontrolled infection~* Positive serologic test for Hepatitis B or a positive serologic or nucleic acid test for Hepatitis C~* HIV seropositivity~* Life expectancy \< 3 months~* Pregnancy or lactation~* Inability to comply with IL-2 treatment regimen~* Uncontrolled cardiac angina or symptomatic congestive heart failure~* Organ transplant (allograft) recipient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interleukin-2 (Type: EXPERIMENTAL): Interleukin-2 (IL-2) will be given daily through an injection under the skin for a period of 8 weeks. To determine the highest safest dose of IL-2, the dose participants receive will increase as lower doses are determined to be safe. There will be three dose levels:~Dose Level -A 0.3 x 106 (IU/m2/d) Dose Level -B 1 x 106 (IU/m2/d) Dose Level-C 3 x 106 (IU/m2/d)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Clinical Performance of the Protecta ICD and CRT-D

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients meeting one of the following criteria can be included in Phase I of the study:~  * Patients indicated (per local indications) for a dual chamber implantable cardioverter defibrillator (DR-ICD)/cardiac resynchronization therapy defibrillator (CRT-D)~ * Patients undergoing a device replacement or upgrade to DR-ICD or CRT-D and with the protocol required leads (patients must be enrolled prior to implant)~* Patients meeting one of the following criteria can be included in Phase II of the study:~  * Patients indicated for a DR-ICD/VR-ICD/CRT-D device and intended to receive a Protecta device~ * Patients undergoing a DR-ICD/VR-ICD/CRT-D device replacement or an upgrade to a Protecta DR-ICD/VR-ICD or CRT-D~ * Patients indicated for a DR-ICD/VR-ICD/CRT-D already implanted with a Protecta device and the protocol required leads, who have not yet been discharged after implant~Exclusion Criteria:~* Patients with a mechanical tricuspid heart valve~* Patients enrolled or intended to participate in any concurrent drug and/or device study, which would confound the results of this trial as determined by Medtronic, during the course of this clinical study~* Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients~* Patients with exclusion criteria required by local law (e.g. age, pregnancy, breast feeding, etc)~* Patients anticipated not being able to complete the study~* Patients unwilling to provide written informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single-chamber detetction (Type: EXPERIMENTAL): Patients implanted with a Protecta VR-ICD.
- Dual-chamber detection (Type: EXPERIMENTAL): Patients implanted with a Protecta DR-ICD or CRT-D.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed written informed consent from the patient's parent/guardian, and assent from the patient prior to conducting of any study-related procedures.~* Patients must be male or female between the age of 12 and 17 years, inclusive.~* Patients must have a clinical diagnosis of GERD made by the investigator based on any of the following factors: history, physical examination, review of systems, laboratory test results, or information from diagnostic testing.~Exclusion Criteria:~* Patients who have used a PPI within 14 days prior to randomization, including over-the-counter Prilosec®.~* Patients who have used any prescription or over-the-counter treatment for symptoms of gastroesophageal reflux disease (GERD), such as Histamine 2 Receptor Antagonists (H2RA) or prokinetics, within 3 days prior to randomization. Antacids may be used, except for those containing bismuth.~* Patients with a known hypersensitivity, allergy, or intolerance to any component of esomeprazole or omeprazole.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete